Oklo
OKLO
$27.01
-2.60%
Oklo Inc. is a pre-revenue advanced nuclear technology developer building liquid-metal fast reactor power plants through its Aurora powerhouse product line, with a dual strategy of selling commercial-scale fission energy to customers and offering used nuclear fuel recycling services in the U.S. market; the company sits within the Utilities/Independent Power Producers sector but behaves operationally like an early-stage deep-tech venture. Oklo is a first-mover among small modular reactor (SMR) developers, differentiating itself through fast-reactor technology capable of running on recycled fuel and through high-profile offtake relationships, including a Meta-linked 1.2-gigawatt Ohio project. The investor narrative has shifted dramatically from AI-datacenter-driven nuclear euphoria to skepticism, with headlines focused on a 76% share-price collapse, persistent cash burn, shareholder dilution, a 2028 commercialization target that offers no near-term revenue catalysts, and sector-wide caution after peer Holtec cancelled its IPO. Bulls point to Big Tech's multi-decade SMR contracting (Amazon-Constellation, Meta-Oklo) and rising government support as validation of the long-term opportunity, while bears argue the equity is priced for a future that remains years and multiple regulatory approvals away.…
OKLO
Oklo
$27.01
Related headlines
Investment Opinion: Should I buy OKLO Today?
Rating: Hold (speculative). Oklo is a pre-revenue deep-tech bet whose equity price reflects long-dated Aurora project value rather than current cash flows, and while the 20-analyst consensus is 'buy' with a $75.375 average target implying +169% upside, the wide $14-$130 target range and recent Neutral/Hold actions from UBS, Citigroup, and Truist argue for patience rather than aggressive accumulation at a fresh 52-week low.
Supporting evidence is mixed. On the positive side, the balance sheet is exceptional — $1.66 billion cash, debt-to-equity of 0.00098, current ratio of 49.08 — and the Meta 1.2GW Ohio offtake plus Amazon-Constellation's 20-year deal validate long-term SMR demand. However, Q2 2026 revenue of $1.21 million, a -60.49% operating margin, -$275.82 million TTM free cash flow, and 26% year-over-year share dilution show the fundamental ramp is years away. Valuation offers no anchor: EV/Sales of 2,579.65x and P/B of 7.11x compare with a Utilities/IPP sector at mid-to-high-teens PE and 1-3x sales, and the negative forward PE of -25.80 means there is no earnings floor.
The biggest risks that could invalidate the thesis are a delayed 2028 commercialization timeline, another dilutive equity raise, and continued sector de-rating following Holtec's cancelled IPO. This Hold would upgrade to Buy on a credible NRC licensing milestone or a second hyperscaler offtake announcement that de-risks the 2028 target, and would downgrade to Sell on a break below the $27.52 52-week low accompanied by a financing announcement. Relative to its own history, P/B has compressed from 13.92x in Q3 2025 to 7.11x today, suggesting the stock is near the bottom of its valuation band — but with no revenue and widening losses, that is more a reflection of deteriorating fundamentals than deep value.
Sign up to view all
OKLO 12-Month Price Forecast
The forward view is bearish over a 12-month horizon because Oklo has no revenue catalyst before 2028, is burning roughly $276 million of free cash flow annually, and trades at an EV/Sales multiple of 2,579.65x that offers no valuation floor. The $1.66 billion cash balance and Meta 1.2GW offtake are genuine long-term assets, but the stock's -98.28 point one-year relative strength versus the S&P 500 and fresh 52-week low show sellers remain in control. The wide $14-$130 analyst range and Neutral/Hold actions from UBS, Citigroup, and Truist confirm low conviction even among bulls. I would upgrade to neutral on a credible NRC licensing milestone or a second hyperscaler contract that de-risks the 2028 timeline, and downgrade further on a break below $27.52 accompanied by a financing announcement.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Oklo's 12-month outlook, with a consensus price target around $72.00 and implied upside of +166.6% versus the current price.
Average Target
$72.00
0 analysts
Implied Upside
+166.6%
vs. current price
Analyst Count
—
covering this stock
Price Range
$14 - $130
Analyst target range
Coverage is robust for a pre-revenue company, with 20 analysts and a consensus recommendation of 'buy' (recommendation mean 2.17 on a scale where lower is more bullish) and an average target price of $75.375 — implying roughly +169% upside from the current $27.97, a gap that signals the sell-side is anchoring to long-term project value rather than near-term fundamentals. Sentiment is more mixed than the headline 'buy' suggests: recent actions from UBS (Neutral), Citigroup (Neutral), Truist (Hold), and Barclays (Overweight) show a split between bulls and cautious holds, and no firm has upgraded recently, consistent with the stock's 82.75% one-year decline and fresh 52-week low. The target range is extraordinarily wide — $14.00 low to $130.00 high, a more than 9x spread — which signals very low conviction and high uncertainty: the $130 high assumes successful Aurora commercialization, multiple Meta-style offtake wins, and a re-rating toward SMR peer multiples, while the $14 low prices in continued cash burn, dilution, regulatory delays, and a sector de-rating (as foreshadowed by Holtec's cancelled IPO). Consensus EPS estimates range from -$1.40 to +$0.003, and revenue estimates from $71.6 million to $580.1 million, further confirming that even the analyst community cannot agree on the shape of the ramp; investors should treat the average target as a scenario-weighted aspiration rather than a near-term price objective, and note that a wide dispersion typically precedes continued volatility rather than a quick re-rating.
Drowning in data?
Find the real signal!
Bulls vs Bears: OKLO Investment Factors
The bear case currently has stronger evidence: Oklo is pre-revenue with widening losses, negative free cash flow of -$275.82 million TTM, accelerating dilution, and a stock at its 52-week low with no technical support. The bull case rests on long-duration optionality — the Meta 1.2GW Ohio deal, $1.66 billion of cash, and a $75.375 average analyst target implying +169% upside — but none of that produces near-term revenue before the 2028 commercialization target. The single most important tension is whether Oklo can convert its offtake pipeline into regulatory approvals and construction milestones before its cash and shareholder patience run out; a credible NRC milestone or additional hyperscaler contract would shift the narrative, while another year of silence likely forces further de-rating and dilution.
Bullish
- Meta 1.2GW Ohio deal validates demand: Oklo's offtake agreement with Meta for a 1.2-gigawatt reactor in Ohio provides third-party validation from a top-tier hyperscaler, anchoring long-term demand for its Aurora powerhouse. This is a concrete commercial commitment in a sector where most SMR developers still lack named customers.
- Fortress balance sheet with $1.66B cash: Cash of $1.66 billion and a current ratio of 49.08, with debt-to-equity of just 0.00098, give Oklo one of the strongest liquidity positions among pre-revenue SMR developers. Interest income of $21.50 million in Q2 2026 partially offsets operating losses, extending the runway.
- Analyst average target implies +169% upside: The 20-analyst consensus is 'buy' (mean 2.17) with an average target of $75.375 versus the $27.97 price, implying roughly +169% upside. The high target of $130 reflects a scenario where Aurora commercialization and additional Meta-style deals re-rate the equity.
- First-mover in fast-reactor fuel recycling: Oklo's liquid-metal fast reactor design can run on recycled used nuclear fuel, a differentiated capability versus light-water SMR peers. The dual commercial-energy and fuel-recycling strategy creates optionality that is not captured in current near-zero revenue.
Bearish
- Pre-revenue with no near-term catalysts: Q2 2026 revenue was just $1.21 million versus $0 in the prior four quarters, and the first commercial Aurora plant is not targeted until 2028. With no meaningful revenue ramp before then, there is no fundamental catalyst to arrest the 82.75% one-year decline.
- Cash burn and dilution accelerating: Free cash flow was -$141.68 million in Q2 alone and -$275.82 million TTM, while shares outstanding rose from 140.1 million in Q2 2025 to 176.2 million in Q2 2026. Capex ramped to $94.09 million in Q2 from $32.81 million in Q1, meaning continued equity issuance is likely.
- Losses widening as R&D and G&A surge: Q2 2026 net loss of -$48.54 million widened from -$33.06 million in Q1 and -$24.69 million a year earlier, with R&D up to $39.47 million from $11.47 million and G&A to $34.21 million from $16.44 million. Operating margin of -60.49% shows the cost base is scaling faster than any revenue.
- Extreme valuation with no earnings floor: EV/Sales of 2,579.65x and P/B of 7.11x capitalize future project value rather than current cash flows, and the negative forward PE of -25.80 offers no valuation support. Against a Utilities/IPP sector trading at mid-to-high-teens PE and 1-3x sales, the premium is binary on execution.
OKLO Technical Analysis
Oklo is in a severe, sustained downtrend: the stock is down 82.75% over the past year and 64.05% year-to-date, and at $27.97 it trades at just 0.3% of its 52-week range (52-week low $27.52, high $171.65) — effectively at the floor of its range and printing fresh 52-week lows as recently as the October 9 headline. This positioning is the textbook definition of a falling knife rather than a value opportunity: the stock has lost roughly 84% peak-to-trough (max drawdown -83.94%), and there is no evidence yet of a durable base forming near the lows. Momentum is uniformly negative and, if anything, deteriorating: the stock fell 21.48% in the past month, 31.96% over three months, and 58.14% over six months, with the most recent session alone down 6.80% from $30.01 to $27.97. Relative strength confirms persistent underperformance versus the S&P 500 — -22.70 points over one month, -34.65 over three months, and -98.28 over one year against an SPY that rose 15.53% — meaning there is no short-term divergence or mean-reversion signal; sellers remain in control. Key levels are stark: the 52-week low of $27.52 is the only visible support, and a decisive break below it would open air with no historical reference points, while any recovery would first need to reclaim round-number psychological levels in the $35–$40 zone (the September consolidation area) before the $50+ region becomes relevant. With a beta of 1.215 the stock is roughly 21.5% more volatile than the market, but that figure understates realized risk given the -83.94% drawdown; average volume of about 9.5 million shares and a short ratio of 3.39 days indicate heavy speculative participation, which argues for small position sizing and strict stop discipline.
Beta
1.22
1.22x market volatility
Max Drawdown
-84.5%
Largest decline past year
52-Week Range
$26-$152
Price range past year
Annual Return
-77.5%
Cumulative gain past year
| Period | OKLO Return | S&P 500 |
|---|---|---|
| 1m | -33.2% | -1.2% |
| 3m | -32.9% | +3.4% |
| 6m | -62.0% | +7.0% |
| 1y | -77.5% | +14.4% |
| ytd | -65.3% | +12.0% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
OKLO Fundamental Analysis
Oklo's revenue trajectory is essentially nascent and non-linear: Q2 2026 revenue was just $1.21 million (versus $0 in Q1 2026, Q4 2025, Q3 2025, and Q2 2025), with the sole disclosed segment being 'Product and Service, Other' at $242,000, so there is no meaningful multi-quarter growth trend to extrapolate — the company remains pre-commercial, with consensus FY revenue estimates of $314.7 million (range $71.6 million to $580.1 million) reflecting expectations for a step-change tied to project milestones rather than an existing book of business. Profitability is deeply negative and worsening in absolute terms: Q2 2026 net income was -$48.54 million (EPS -$0.28) versus -$33.06 million in Q1 2026 and -$24.69 million in Q2 2025, with operating income of -$73.19 million, EBITDA of -$51.35 million, and an operating margin of -60.49%; R&D spending rose to $39.47 million from $11.47 million a year earlier and G&A to $34.21 million from $16.44 million, so the loss is widening because the company is investing ahead of commercialization, not because of margin compression in an existing business. The balance sheet is the one genuine strength: debt-to-equity is effectively zero at 0.00098, the current ratio is 49.08, cash stood at $1.66 billion at quarter-end after $670 million of common stock issued in Q2 and $1.18 billion in Q1, and interest income of $21.50 million partially offsets operating losses — but free cash flow is deeply negative at -$141.68 million in Q2 alone (-$275.82 million TTM), capex is ramping ($94.09 million in Q2 versus $32.81 million in Q1), and ROE is -7.16% with ROA of -6.65%, meaning the company is entirely dependent on external equity financing and dilution (shares outstanding rose from 140.1 million in Q2 2025 to 176.2 million in Q2 2026) to fund its path to a 2028 first commercial plant.
Quarterly Revenue
$1210000.0B
2026-06
Revenue YoY Growth
N/A
YoY Comparison
Gross Margin
40.4%
Latest Quarter
Free Cash Flow
$-275816000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is OKLO Overvalued?
Because Oklo's net income is negative (Q2 2026 net income -$48.54 million, trailing EPS -$0.01 and forward EPS estimate -$0.67), the PE ratio is not meaningful — the trailing PE of -99.67 and forward PE of -25.80 are artifacts of losses — so the appropriate primary metric is price-to-sales, supplemented by EV/Sales and price-to-book; PS is reported as 0 in the valuation feed (reflecting negligible trailing revenue), while EV/Sales is an extreme 2,579.65x and P/B is 7.11x, underscoring that the market is capitalizing future project value, not current cash flows. The forward PE of -25.80 versus trailing -99.67 implies the market expects losses to narrow materially as revenue scales toward the $314.7 million consensus estimate, but with no positive earnings in sight the multiple offers no valuation floor. Peer comparison is difficult because Oklo's revenue base is near zero, but against a Utilities/Independent Power Producers sector that typically trades at mid-to-high-teens PE and 1–3x sales, Oklo's 7.11x book and 2,579x EV/Sales represent a massive premium that can only be justified by successful execution of the Aurora pipeline and fuel-recycling optionality — a binary, multi-year bet rather than a defensible current valuation. Historically, Oklo's own P/B has compressed from 13.92x in Q3 2025 and 11.26x in Q2 2025 to 7.11x today, and its PS ratio has collapsed from 7,621x in Q2 2026, showing the market has been steadily de-rating the story; the stock is now near the bottom of its own historical valuation band, which could signal either deep value or continued fundamental deterioration given the absence of revenue and the widening losses.
PE
-99.7x
Latest Quarter
vs. Historical
N/A
5-Year PE Range 17x~59x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
-88.6x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks are severe for a pre-commercial company. Oklo generated only $1.21 million of revenue in Q2 2026 while burning -$141.68 million of free cash flow in the quarter and -$275.82 million TTM, with net loss widening to -$48.54 million from -$24.69 million a year earlier. R&D of $39.47 million and G&A of $34.21 million in Q2 reflect a cost base scaling well ahead of revenue, and shares outstanding rose from 140.1 million to 176.2 million year-over-year, a roughly 26% dilution. The $1.66 billion cash balance and 49.08 current ratio provide a multi-year runway, but capex ramping to $94.09 million in Q2 from $32.81 million in Q1 means the company remains dependent on external equity financing until the 2028 first commercial plant.
Market and competitive risks center on valuation compression and sector sentiment. EV/Sales of 2,579.65x and P/B of 7.11x leave no fundamental floor, and the stock's beta of 1.215 understates realized risk given an -83.94% max drawdown. Peer Holtec's cancelled IPO signals shifting market sentiment on AI-datacenter nuclear demand, while X-Energy's U.K. regulatory progress and NuScale's utility-focused Amazon-linked strategy highlight intensifying competition for SMR contracts. The stock's -98.28 point one-year relative strength versus the S&P 500 confirms persistent sector rotation away from speculative nuclear names.
Worst-case scenario: a delayed NRC approval or a failed Aurora construction milestone combines with a broader SMR de-rating, forcing another equity raise at depressed prices. In that chain, the stock could retest and break its 52-week low of $27.52 and approach the analyst low target of $14.00, implying roughly -50% from the current $27.97. A move to the $14 bear target would represent a -50% loss, and a break below $27.52 opens air with no historical support given the stock's short trading history since its May 2024 listing.
FAQ
The most severe risk is financial: free cash flow of -$275.82 million TTM and a Q2 2026 net loss of -$48.54 million require continued equity financing, with shares outstanding already up 26% year-over-year to 176.2 million. Second is regulatory and execution risk, as the 2028 first commercial Aurora plant depends on NRC approvals that have not yet been granted. Third is competitive and sector risk, with Holtec's cancelled IPO and X-Energy's U.K. regulatory progress highlighting intensifying SMR competition and shifting sentiment. Fourth is valuation compression risk, with EV/Sales of 2,579.65x leaving no fundamental floor and a beta of 1.215 understating the -83.94% realized drawdown.
The 12-month forecast has three scenarios: a 20% probability bull case of $75-$130 on an NRC licensing milestone or second hyperscaler offtake, a 50% probability base case of $30-$50 as the company grinds through licensing without revenue, and a 30% probability bear case of $14-$27.52 on a regulatory delay or dilutive equity raise. The base case is most likely, assuming no major NRC setback but also no accelerated approval before 2028, with cash burn of roughly $250-$300 million annually funded without a distressed raise. The wide $14-$130 analyst target range confirms the outcome is binary on execution rather than a smooth re-rating.
OKLO is difficult to value on earnings because it is pre-revenue, but on sales and book it looks expensive relative to peers. EV/Sales of 2,579.65x and P/B of 7.11x compare with a Utilities/IPP sector typically at 1-3x sales and mid-to-high-teens PE, a massive premium that capitalizes future Aurora project value. The negative forward PE of -25.80 and trailing PE of -99.67 offer no earnings floor. However, P/B has compressed from 13.92x in Q3 2025 to 7.11x today, placing the stock near the bottom of its own historical valuation band. The market is pricing in successful 2028 commercialization and additional offtake wins; any delay would make the current multiple look overvalued.
From a risk/reward perspective, OKLO is a high-risk speculative buy only for investors who can tolerate an -83.94% max drawdown and a multi-year wait. The 20-analyst consensus is 'buy' with a $75.375 average target implying +169% upside from $27.97, but the $14-$130 target range signals very low conviction. The biggest downside risk is a break below the $27.52 52-week low toward the $14 analyst low, roughly -50%. It is a good buy only for risk-tolerant investors with a 3-5 year horizon who size positions small and can withstand further dilution, not for near-term traders or conservative portfolios.
OKLO is suitable only for long-term, risk-tolerant investors with a minimum 3-5 year holding period, because the first commercial Aurora plant is not targeted until 2028 and meaningful revenue is unlikely before then. The stock pays no dividend (yield 0%) and has a beta of 1.215, but realized volatility is far higher given the -83.94% max drawdown and -21.48% one-month decline. Short-term trading is extremely hazardous at a fresh 52-week low with no technical support below $27.52. Earnings visibility is essentially zero, with analyst revenue estimates ranging from $71.6 million to $580.1 million, so position sizing should be small and entry staged rather than lump-sum.